Historical source coverage

2025

376 selected records with a cited source date in 2025, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.

Explore 2025 by record type

3 types

December 2025

51 records on this page

Regulatory · Glatiramer acetate

Drugs@FDA application ANDA214741

The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Literature metadata · Oxytocin

How factors of the therapeutic alliance interact with oxytocin neurotransmission in psychotherapy.

PubMed lists PMID 41458027 in Frontiers in psychiatry as Journal Article, Review, with publication-date metadata of 2025-12-11 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Vasopressin

Arginine vasopressin deficiency after surgical ligation of an unruptured anterior communicating artery aneurysm - a case report and literature review.

PubMed lists PMID 41341140 in Frontiers in endocrinology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Plecanatide

ClinicalTrials.gov record NCT03596905

PeptideScanner retained ClinicalTrials.gov record NCT03596905 at 2026-07-30T18:18:33.534Z. Its registry update date was 2025-12-31, and PeptideScanner's reviewed identity mapping was plecanatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Emideltide

Immunohistochemical distribution of DSIP immunoreactivity in the human hypothalamus during the first postnatal year. A preliminary report.

PubMed lists PMID 11321250 in Folia biologica as Journal Article, with publication-date metadata of 2001 (year precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Leuprolide

ClinicalTrials.gov record NCT03809000

PeptideScanner retained ClinicalTrials.gov record NCT03809000 at 2026-07-30T18:18:33.523Z. Its registry update date was 2025-12-30, and PeptideScanner's reviewed identity mapping was leuprolide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT05702931

PeptideScanner retained ClinicalTrials.gov record NCT05702931 at 2026-07-30T18:18:33.515Z. Its registry update date was 2025-12-29, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Tirzepatide

ClinicalTrials.gov record NCT07128082

PeptideScanner retained ClinicalTrials.gov record NCT07128082 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-23, and PeptideScanner's reviewed identity mapping was tirzepatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Vasopressin

ClinicalTrials.gov record NCT05568160

PeptideScanner retained ClinicalTrials.gov record NCT05568160 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was vasopressin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Octreotide

ClinicalTrials.gov record NCT07262957

PeptideScanner retained ClinicalTrials.gov record NCT07262957 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Efpeglenatide

Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes.

PubMed lists PMID 41403449 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug efpeglenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Pasireotide

ClinicalTrials.gov record NCT02713776

PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Elamipretide

Federal Register notice 2025-23409

The Federal Register published notice 2025-23409, attributed to FDA and its parent HHS department, on 2025-12-19. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide),” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Tirzepatide

ClinicalTrials.gov record NCT07265752

PeptideScanner retained ClinicalTrials.gov record NCT07265752 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Tirzepatide

ClinicalTrials.gov record NCT07292519

PeptideScanner retained ClinicalTrials.gov record NCT07292519 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT05891587

PeptideScanner retained ClinicalTrials.gov record NCT05891587 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Maridebart cafraglutide

ClinicalTrials.gov record NCT06987695

PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT07029009

PeptideScanner retained ClinicalTrials.gov record NCT07029009 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Icatibant

Icatibant Use During Pregnancy: A South African Case Series.

PubMed lists PMID 41133754 in Journal of investigational allergology & clinical immunology as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · LL-37

Decoding LL-37: Structure and antimicrobial mechanisms against microbial threats.

PubMed lists PMID 41270816 in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases as Journal Article, Review, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Tirzepatide

ClinicalTrials.gov record NCT07176663

PeptideScanner retained ClinicalTrials.gov record NCT07176663 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-15, and PeptideScanner's reviewed identity mapping was tirzepatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Thymosin alpha-1

Aging and Thymosin Alpha-1.

PubMed lists PMID 41373628 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2025-11-27 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Aviptadil

Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.

PubMed lists PMID 41368449 in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine as Journal Article, Review, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT07280221

PeptideScanner retained ClinicalTrials.gov record NCT07280221 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Elamipretide

ClinicalTrials.gov record NCT05168774

PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT04102189

PeptideScanner retained ClinicalTrials.gov record NCT04102189 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-11, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Difelikefalin

Difelikefalin for Hemodialysis Patients with Pruritus in Japan.

PubMed lists PMID 38320524 in NEJM evidence as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Glucagon + 5 more

Federal Register notice 2025-22131

The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT04788511

PeptideScanner retained ClinicalTrials.gov record NCT04788511 at 2026-07-30T18:18:33.488Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Maridebart cafraglutide

PubMed record PMID 41337724

PeptideScanner retained PubMed bibliographic metadata for PMID 41337724 at 2026-07-30T18:19:18.413Z. PubMed recorded a metadata revision date of 2025-12-03 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT01225055

PeptideScanner retained ClinicalTrials.gov record NCT01225055 at 2026-07-30T18:18:33.512Z. Its registry update date was 2025-12-02, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Trofinetide

Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.

PubMed lists PMID 37291210 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Daptomycin

Analytical Methods for Daptomycin Determination: Applications in Biological Matrices and Pharmaceutical Formulations.

PubMed lists PMID 41321327 in Critical reviews in analytical chemistry as Journal Article, Review, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

November 2025

29 records on this page

Clinical trials · Pegcetacoplan

ClinicalTrials.gov record NCT05148299

PeptideScanner retained ClinicalTrials.gov record NCT05148299 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Lixisenatide

ClinicalTrials.gov record NCT03439943

PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Dalbavancin

Drugs@FDA application ANDA218929

The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Clinical trials · Metreleptin

ClinicalTrials.gov record NCT04026178

PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Leuprolide

ClinicalTrials.gov record NCT02023463

PeptideScanner retained ClinicalTrials.gov record NCT02023463 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Bivalirudin

BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis.

PubMed lists PMID 41029353 in BMC medicine as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2025-09-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Glucagon + 1 more

Federal Register notice 2025-20548

The Federal Register published notice 2025-20548, attributed to FDA and its parent HHS department, on 2025-11-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Vosoritide

Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report.

PubMed lists PMID 41078071 in Hormone research in paediatrics as Case Reports, Journal Article, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT07242612

PeptideScanner retained ClinicalTrials.gov record NCT07242612 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-21, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Carfilzomib

ClinicalTrials.gov record NCT02937571

PeptideScanner retained ClinicalTrials.gov record NCT02937571 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was carfilzomib.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Tesamorelin

ClinicalTrials.gov record NCT03375788

PeptideScanner retained ClinicalTrials.gov record NCT03375788 at 2026-07-30T18:19:48.220Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was tesamorelin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT07239570

PeptideScanner retained ClinicalTrials.gov record NCT07239570 at 2026-07-30T18:19:48.218Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Cerebrolysin

ClinicalTrials.gov record NCT06052787

PeptideScanner retained ClinicalTrials.gov record NCT06052787 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was cerebrolysin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Eloralintide

ClinicalTrials.gov record NCT06916091

PeptideScanner retained ClinicalTrials.gov record NCT06916091 at 2026-11-16T01:48:01.052Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was eloralintide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Setmelanotide

Carbocyclic setmelanotide analogs maintain biochemical potency at melanocortin 4 receptors.

PubMed lists PMID 39394922 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2024-10-12 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Elamipretide

Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

PubMed lists PMID 40816230 in Molecular genetics and metabolism as Journal Article, Case Reports, Review, with publication-date metadata of 2025-08-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Palopegteriparatide

Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA).

PubMed lists PMID 41134515 in Advances in therapy as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Eptifibatide

Prophylactic Intra-Arterial Eptifibatide in Stent-Assisted Coiling and Flow Diverter Treatment of Cerebral Aneurysms: A Single-Center Retrospective Analysis.

PubMed lists PMID 41227129 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-10-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT06499857

PeptideScanner retained ClinicalTrials.gov record NCT06499857 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-14, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT06446531

PeptideScanner retained ClinicalTrials.gov record NCT06446531 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Dalbavancin

Drugs@FDA application ANDA217591

The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

October 2025

23 records on this page

Literature metadata · Degarelix

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.

PubMed lists PMID 35923949 in Frontiers in public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-07-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Pegcetacoplan

ClinicalTrials.gov record NCT05096403

PeptideScanner retained ClinicalTrials.gov record NCT05096403 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-10-30, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Afamelanotide

Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective.

PubMed lists PMID 40692281 in Clinical and experimental dermatology as Journal Article, with publication-date metadata of 2025-10-27 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Elamipretide

ClinicalTrials.gov record NCT05162768

PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Dalbavancin

Drugs@FDA application ANDA219465

The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Clinical trials · Efinopegdutide

ClinicalTrials.gov record NCT06052566

PeptideScanner retained ClinicalTrials.gov record NCT06052566 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-10-22, and PeptideScanner's reviewed identity mapping was efinopegdutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Icatibant

Icatibant for hereditary angioedema.

PubMed lists PMID 20135020 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-12 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Teduglutide

Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries.

PubMed lists PMID 40764045 in BMJ open gastroenterology as Journal Article, with publication-date metadata of 2025-08-05 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Metreleptin

Metreleptin In SHORT Syndrome With Uncontrolled Diabetes.

PubMed lists PMID 41080980 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-10-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Tirzepatide

ClinicalTrials.gov record NCT06994338

PeptideScanner retained ClinicalTrials.gov record NCT06994338 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-14, and PeptideScanner's reviewed identity mapping was tirzepatide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Exenatide + 1 more

Federal Register notice 2025-19281

The Federal Register published notice 2025-19281, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide.

Source: Federal Register via GovInfo ↗

→

Regulatory · Semaglutide

Federal Register notice 2025-19345

The Federal Register published notice 2025-19345, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT04466345

PeptideScanner retained ClinicalTrials.gov record NCT04466345 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-02, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · MOTS-c

MOTS-c: an equal opportunity insulin sensitizer.

PubMed lists PMID 30788534 in Journal of molecular medicine (Berlin, Germany) as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-02-20 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · MOTS-c

A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.

PubMed lists PMID 33468709 in Aging as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-01-19 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

September 2025

31 records on this page

Literature metadata · Icatibant

Exceptional treatment of COVID-19 pneumonia with icatibant.

PubMed lists PMID 35275476 in Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias as Journal Article, with publication-date metadata of 2022-04 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Calcitonin salmon

Drugs@FDA application ANDA216294

The official Drugs@FDA dataset lists original submission 1 for ANDA 216294 with status AP dated 2025-09-26, and names calcitonin salmon among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT06639464

PeptideScanner retained ClinicalTrials.gov record NCT06639464 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-26, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Ziconotide

Can Ziconotide Be Used to Replace Opioids? Exploratory Clinical Experience in 5 Patients Treated in the Pain Unit.

PubMed lists PMID 40985013 in Journal of pain research as Journal Article, with publication-date metadata of 2025-09-17 (day precision). PeptideScanner associated the retained record with the identity slug ziconotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Bivalirudin

Federal Register notice 2025-18453

The Federal Register published notice 2025-18453, attributed to FDA and its parent HHS department, on 2025-09-24. Its official title is “Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Leuprolide

ClinicalTrials.gov record NCT06348264

PeptideScanner retained ClinicalTrials.gov record NCT06348264 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-23, and PeptideScanner's reviewed identity mapping was leuprolide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Tirzepatide

ClinicalTrials.gov record NCT06847399

PeptideScanner retained ClinicalTrials.gov record NCT06847399 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · LL-37

Significance of the LL-37 Peptide Delivered from Human Cathelicidin in the Pathogenesis, Treatment, and Diagnosis of Sepsis.

PubMed lists PMID 40960088 in Archivum immunologiae et therapiae experimentalis as Journal Article, Review, with publication-date metadata of 2025-09-07 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Tirzepatide

ClinicalTrials.gov record NCT06901245

PeptideScanner retained ClinicalTrials.gov record NCT06901245 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-16, and PeptideScanner's reviewed identity mapping was tirzepatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Metreleptin

Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2.

PubMed lists PMID 40860570 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Teduglutide

ClinicalTrials.gov record NCT03562130

PeptideScanner retained ClinicalTrials.gov record NCT03562130 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was teduglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Linaclotide

Linaclotide as a Single Agent Bowel Preparation Regimen Before Colonoscopy.

PubMed lists PMID 39530977 in The American surgeon as Journal Article, with publication-date metadata of 2024-11-12 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Abaloparatide

▼Abaloparatide (Eladynos) for osteoporosis.

PubMed lists PMID 40588314 in Drug and therapeutics bulletin as Journal Article, with publication-date metadata of 2025-06-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Amycretin

PubMed record PMID 40550232

PeptideScanner retained PubMed bibliographic metadata for PMID 40550232 at 2026-07-30T18:22:52.359Z. PubMed recorded a metadata revision date of 2025-09-11 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Clinical trials · Octreotide

ClinicalTrials.gov record NCT03000946

PeptideScanner retained ClinicalTrials.gov record NCT03000946 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Leuprolide

ClinicalTrials.gov record NCT03678025

PeptideScanner retained ClinicalTrials.gov record NCT03678025 at 2026-07-30T18:22:04.918Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was leuprolide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Mazdutide

PubMed record PMID 40929642

PeptideScanner retained PubMed bibliographic metadata for PMID 40929642 at 2026-07-30T18:22:54.035Z. PubMed recorded a metadata revision date of 2025-09-10 and an Entrez history date of 2025-09-10. PeptideScanner associated this retained record with the identity slug mazdutide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Mazdutide

PubMed record PMID 40929641

PeptideScanner retained PubMed bibliographic metadata for PMID 40929641 at 2026-07-30T18:22:54.035Z. PubMed recorded a metadata revision date of 2025-09-10 and an Entrez history date of 2025-09-10. PeptideScanner associated this retained record with the identity slug mazdutide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT05548647

PeptideScanner retained ClinicalTrials.gov record NCT05548647 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Carfilzomib

Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.

PubMed lists PMID 40672881 in HemaSphere as Journal Article, Review, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Octreotide

ClinicalTrials.gov record NCT06193616

PeptideScanner retained ClinicalTrials.gov record NCT06193616 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-05, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Carfilzomib

ClinicalTrials.gov record NCT04191616

PeptideScanner retained ClinicalTrials.gov record NCT04191616 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-09-04, and PeptideScanner's reviewed identity mapping was carfilzomib.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Cotadutide

ClinicalTrials.gov record NCT05364931

PeptideScanner retained ClinicalTrials.gov record NCT05364931 at 2026-11-16T01:47:38.899Z. Its registry update date was 2025-09-03, and PeptideScanner's reviewed identity mapping was cotadutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Retatrutide

Retatrutide.

PubMed lists PMID 39429457 in Clinical diabetes : a publication of the American Diabetes Association as Journal Article, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

August 2025

27 records on this page

Literature metadata · LL-37

Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications.

PubMed lists PMID 40869425 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2025-08-21 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Motixafortide

ClinicalTrials.gov record NCT06547112

PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Bivalirudin

ClinicalTrials.gov record NCT03822975

PeptideScanner retained ClinicalTrials.gov record NCT03822975 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was bivalirudin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT06986993

PeptideScanner retained ClinicalTrials.gov record NCT06986993 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Palopegteriparatide

Federal Register notice 2025-16269

The Federal Register published notice 2025-16269, attributed to FDA and its parent HHS department, on 2025-08-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Cagrilintide

PubMed record PMID 40609154

PeptideScanner retained PubMed bibliographic metadata for PMID 40609154 at 2026-07-30T18:24:19.064Z. PubMed recorded a metadata revision date of 2025-08-26 and an Entrez history date of 2025-07-03. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT06691243

PeptideScanner retained ClinicalTrials.gov record NCT06691243 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-24, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT05530577

PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Setmelanotide

Development of Dysplastic Nevi in a Child with LEPR Deficiency Treated with Setmelanotide.

PubMed lists PMID 40836563 in Journal of clinical research in pediatric endocrinology as Journal Article, with publication-date metadata of 2025-08-21 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Triptorelin

ClinicalTrials.gov record NCT07128394

PeptideScanner retained ClinicalTrials.gov record NCT07128394 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-08-19, and PeptideScanner's reviewed identity mapping was triptorelin.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Pramlintide

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.

PubMed lists PMID 19502544 in Diabetes care as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-06-05 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Bivalirudin

ClinicalTrials.gov record NCT05984537

PeptideScanner retained ClinicalTrials.gov record NCT05984537 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-12, and PeptideScanner's reviewed identity mapping was bivalirudin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Motixafortide

ClinicalTrials.gov record NCT05618301

PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Teduglutide

Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report.

PubMed lists PMID 40771220 in Frontiers in nutrition as Case Reports, Journal Article, with publication-date metadata of 2025-07-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Degarelix

Degarelix acetate for the treatment of prostate cancer.

PubMed lists PMID 20069136 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-10 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Exenatide

Federal Register notice 2025-14683

The Federal Register published notice 2025-14683, attributed to FDA and its parent HHS department, on 2025-08-04. Its official title is “Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Vasopressin

Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?

PubMed lists PMID 40731360 in Critical care (London, England) as Journal Article, Review, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

July 2025

39 records on this page

Clinical trials · Cerebrolysin

ClinicalTrials.gov record NCT05821075

PeptideScanner retained ClinicalTrials.gov record NCT05821075 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-07-31, and PeptideScanner's reviewed identity mapping was cerebrolysin.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Pegcetacoplan

Treatment of geographic atrophy: an update on data related to pegcetacoplan.

PubMed lists PMID 37815317 in Current opinion in ophthalmology as Review, Journal Article, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Terlipressin

Terlipressin for hepatorenal syndrome.

PubMed lists PMID 38353275 in Current opinion in gastroenterology as Review, Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Abaloparatide

Biodegradable Nanoflowers with Abaloparatide Spatiotemporal Management of Functional Alveolar Bone Regeneration.

PubMed lists PMID 38350110 in Nano letters as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-13 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Glatiramer acetate

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

PubMed lists PMID 25062935 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2014-07-26 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Terlipressin

Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.

PubMed lists PMID 35838488 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-08-03 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Eptifibatide

Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor.

PubMed lists PMID 35926348 in Thrombosis research as Journal Article, with publication-date metadata of 2022-07-25 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Elamipretide

Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.

PubMed lists PMID 34623544 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-10-08 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Elamipretide

Targeting mitochondrial dysfunction with elamipretide.

PubMed lists PMID 35037146 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-01-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · MOTS-c

MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease.

PubMed lists PMID 36066139 in European review for medical and pharmacological sciences as Journal Article, with publication-date metadata of 2022-08 (month precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Lutetium Lu 177 dotatate

ClinicalTrials.gov record NCT06395402

PeptideScanner retained ClinicalTrials.gov record NCT06395402 at 2026-11-16T01:36:36.861Z. Its registry update date was 2025-07-22, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Dasiglucagon

ClinicalTrials.gov record NCT05378672

PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Gallium Ga 68 dotatate

ClinicalTrials.gov record NCT03448458

PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Glepaglutide

ClinicalTrials.gov record NCT03690206

PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Pegcetacoplan

Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.

PubMed lists PMID 40280279 in American journal of ophthalmology as Journal Article, Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Amycretin

PubMed record PMID 40550229

PeptideScanner retained PubMed bibliographic metadata for PMID 40550229 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Amycretin

PubMed record PMID 40550231

PeptideScanner retained PubMed bibliographic metadata for PMID 40550231 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.

Source: PubMed ↗

→

Literature metadata · Cerebrolysin

Cerebrolysin for vascular dementia.

PubMed lists PMID 23440834 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2013-01-31 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Cerebrolysin

Cerebrolysin for acute ischaemic stroke.

PubMed lists PMID 26083192 in The Cochrane database of systematic reviews as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2015-06-17 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Daptomycin

Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series.

PubMed lists PMID 39028390 in Infection as Systematic Review, Journal Article, Case Reports, with publication-date metadata of 2024-07-19 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Orforglipron

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

PubMed lists PMID 38091541 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Orforglipron

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

PubMed lists PMID 38091542 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Cerebrolysin

[Cerebrolysin with reperfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CEREHETIS trial].

PubMed lists PMID 40577185 in Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova as Journal Article, Randomized Controlled Trial, English Abstract, with publication-date metadata of 2025 (year precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Retatrutide

Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

PubMed lists PMID 37888925 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→